23 Jul, 2026
According to Straits Research, the global butterfly needle sets market size was valued at $304.46 million in 2025 and is projected to grow from $329.73 million in 2026 to $624.01 million by 2034 at a CAGR of 8.3% during the forecast period 2026-2034.
Butterfly needle sets are also winged infusion sets and scalp vein sets. These sets are used for vein blood extraction, IV drug infusions, and IV rehydration. Butterfly needles are used more frequently for blood transfusions than alternative products because they are less expensive, more efficient, and more painful than those alternatives.
Due to the rise in chronic diseases like cancer, cardiovascular disease, cancer, and intravenous therapy, butterfly needles are in high demand. As a result, more people are collecting blood using butterfly needles. For instance, according to the World Federation of Hemophilia, 78,500 cases of von Willebrand disease and 210,454 cases of hemophilia were reported globally in 2018. Additionally, the widespread use of intravenous therapy, cancer treatments, and blood transfusions has been brought on by the current increase in cancer cases and other fatal diseases. The market for butterfly needle sets is expanding due to the growing use of butterfly needles for delivering chemotherapy fluids and medication fluids.
It is projected that there would be additional market potential for butterfly needles in a variety of applications due to their benefits. Small or narrow veins, such as those in infants or the elderly, are less painful to access with these needles. Additionally, they are less likely to cause severe bleeding, nerve damage, or vein collapse once removed. Another feature of more recent models is a slide-and-lock sheath, which automatically slides over the needle as it is extracted from a vein to lessen the risk of needlestick injuries and eliminate the need for extra needles.
Asia-Pacific is the most significant contributor to the global butterfly needle sets market and is expected to grow at a CAGR of 9.4% during the forecast period. In Asia-Pacific, the butterfly needle set market is the biggest and is growing quickly. It is the most lucrative market because of the enormous unrealized potential there. The market for Asia-Pacific butterfly needle sets is expected to grow faster than average due to the rising purchasing power of populous countries like China and Japan. In addition, the market is expanding due to factors like the increase in blood donation clinics in this area due to population growth and the growth of the Thalassemic, Hemophilic, and cancer patient pools. Significant key players like B. Braun Melsungen AG, ISOMed, BioMatrix S.r.l., Nipro Corporation, and Kawasumi Laboratories, Inc. are also anticipated to fuel the market's growth.
North America is expected to grow at a CAGR of 7.80% during the forecast period. Cancer and bleeding disorders are the two chronic diseases for which butterfly needles are most frequently used. The U.S. has the largest market share for butterfly needle sets in North America, followed by Canada. This results from major U.S. industry players like Becton, Dickinson and Company, Cardinal Health, Inc., Greiner Bio-One North America, Inc., Medline Industries, Inc., JMS North America Corporation, and Terumo Corporation. 17,757 Americans were diagnosed with hemophilia in 2018. Normal blood clotting is impaired by hemophilia, a genetic blood disorder. Regulations governing blood collection and butterfly needle sets in clinical trials also contribute to this market's growth.
sales@straitsresearch.com